IQVIA Holdings IQV
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
IQVIA Holdings (IQV) Business Model and Operations Summary
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Key Insights
IQVIA Holdings (IQV) Core Market Data and Business Metrics
Latest Closing Price
$158.16Market Cap
$26.77 BillionAverage Trade Volume
2,291,653 SharesPrice-Earnings Ratio
21.58CEO
Mr. Ari BousbibTotal Employees
89,000Current Dividend
No dividendIPO Date
May 9, 2013SIC Description
Services-commercial Physical & Biological ResearchPrimary Exchange
New York Stock ExchangeHeadquarters
2400 Ellis Road, Durham, NC, 27703
Earnings Reports
Expected vs. Actual Quarterly Earnings-Per-Share & Revenue
Short Volume
Daily short volume activity identifies short-term trading pressure and potential price volatility
Short Interest
Bi-monthly short interest levels can be used to gauge bearish market sentiment and short squeeze potential
Revenue Breakdown
Distribution of revenue across unique business segments & geographies
Cash Flow Statement
April 1, 2024 to March 31, 2025
| Metric | Value |
|---|---|
| Net Cash Flow | $296 Million |
| Net Cash Flow From Operating Activities | $2.76 Billion |
| Net Cash Flow, Continuing | $297 Million |
| Net Cash Flow From Financing Activities | $-1.03 Billion |
| Net Cash Flow From Investing Activities, Continuing | $-1.44 Billion |
| Exchange Gains/Losses | $-1 Million |
Income Statement
April 1, 2024 to March 31, 2025
| Metric | Value |
|---|---|
| Costs And Expenses | $13.85 Billion |
| Selling, General, and Administrative Expenses | $1.99 Billion |
| Net Income/Loss Available To Common Stockholders, Basic | $1.33 Billion |
| Diluted Earnings Per Share | $7.33 |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Income/Loss From Equity Method Investments | $-5 Million |
Comprehensive Income
April 1, 2024 to March 31, 2025
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $-29 Million |
| Comprehensive Income/Loss Attributable To Parent | $1.30 Billion |
| Comprehensive Income/Loss | $1.27 Billion |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
April 1, 2024 to March 31, 2025
| Metric | Value |
|---|---|
| Other Non-current Assets | $16.38 Billion |
| Current Assets | $5.91 Billion |
| Equity Attributable To Noncontrolling Interest | $8 Million |
| Noncurrent Assets | $21.41 Billion |
| Equity | $5.99 Billion |
| Liabilities And Equity | $27.32 Billion |
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |